Potent aromatase inhibitors through fungal transformation of anti-cancer drug testolactone: An approach towards treatment of breast cancer

ABSTRACT

Biotransformation of an aromatase inhibitor, testolactone (1), yielded five new metabolites, 7α-hydroxy-3-oxo-13,17-secoandrosta-1,4-dieno-17,13α-lactone (2), 7β-hydroxy-3-oxo-13,17-seco-5β-androsta-1-eno-17,13α-lactone (3), 3α,11β-dihydroxy-13,17-seco-5β-androsta-17,13α-lactone (4), 4β,5β-epoxy-3β-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (5), and 4β,5β-epoxy-3α-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (6). Aromatase (estrogen synthase) involves in the synthesis of estrogen, and promotes the growth of breast cancerous cells. It is a key target for the discovery of chemotherapeutic agents against ER+ (estrogen-positive) breast-cancers and several other diseases caused by overexpression of aromatase enzyme. Metabolites 3 (IC50=8.60±0.402 nM), and 4 (IC50=9.23±1.31 nM) were identified as potent inhibitors against human aromatase enzyme, in comparison to 1 (IC50=0.716±0.031 μM), and the standard aromatase inhibiting drug, exemestane (IC50=0.232±0.031 μM). Derivatives 2 (IC50=11.68±0.73 μM), 5 (IC50=10.37±0.50 μM) and 6 (IC50=0.82±0.059 μM) have also a good inhibition against aromatase enzyme. Therefore, metabolites 2-6 have the potential to serve as therapeutic agents against diseases caused by aromatase enzyme, including breast cancer.

BACKGROUND OF THE INVENTION

Breast cancers are highly prevalent life-threatening cancers, affecting millions of women every year globally. They are diverse and heterogeneous group of diseases at histological, molecular, and systemic levels, having various implications for physicians, and patients. Around 80% of breast cancers are estrogen dependent (ER+), require estrogens for their growth. Estrogens are hormones that play an important role in the reproduction, and in the development of female organs. The increased level of estrogens due to the overexpression of estrogen synthase (aromatase) in the body, promotes the growth of breast tumors. Aromatase is an enzyme that catalyzes the conversion of androgen to estrogen, i.e. steroidal ring “A” into aromatic state. Therefore, inhibition of aromatase enzyme can effectively lower the production of estrogens. Estrogen responsive breast cancer can thus be treated by inhibiting the action of aromatase enzyme in the body [Ghuge et al., Curr. Enzym. Inhib., vol. 16(1), pp. 45-62 (2020); Waks and Winer, JAMA, vol. 321(3), pp. 288-300 (2019); Sun et al., Int. J. Biol. Sci., vol. 13(11), pp. 1387-1397 (2017)].

Currently available aromatase inhibitors have many adverse effects on human body, including nausea, headache, osteoporosis, fatigue, hot flushes, skin reactions, and cardiovascular diseases. This makes them difficult to tolerate for 2-5 years, required for the effective post-surgical treatment of ER+ breast cancer. It would therefore, be a great advantageous to develop even more potent aromatase inhibitors with better pharmacodynamics profile.

Testolactone (1) (3-oxo-13,17-secoandrosta-1,4-dieno-17,13α-lactone), a synthetic steroidal anti-cancer drug, was previously marketed under the brand name of Teslac for the treatment of estrogen responsive breast cancer. The preliminary action of testolactone (1) is the inhibition of aromatase enzyme to block the production of estrogens, and to prevents the growth of cancer cells in breasts. Compound 1 has also been reported as anti-estrogens and anti-carcinogens, and for the treatment of disorders due to the imbalance between androgen and estrogen actions, such as gynecomastia, and prostate cancer and prostatic hyperplasia [Lone and Bhat, Steroids, vol. 96, pp. 164-168 (2015); Dunkel, Mol Cell Endocrinol., vol. 254, pp. 207-216 (2006); Carel et al., Hum. Reprod. Update, vol. 10(2), pp. 135-147 (2004); Lombardi, Biochim. Biophys. Acta-Molecular Basis of Disease, vol. 1587(2-3), pp. 326-337 (2002)].

Whole-cell biocatalysis is a robust approach to synthesize compounds whose structures resemble to parent drugs (substrate). This technique is effectively used where synthetic methodologies are expensive, and difficult. It is a selective, low-cost, and eco-friendly technique, involves the use of bacteria, fungi, yeast, plants, etc. Participation of a variety of enzymes during the biotransformation by whole-cell systems yields regio-, chemo-, and stereo-selective analogues of existing drugs, eliminating the use of toxic and expensive catalysts and reagents [Siddiqui et al., J. Adv. Res., vol. 24, pp. 69-78 (2020); Sultana, Steroids, vol. 136, pp. 76-92 (2018); Choudhary et al., Front. Pharmacol., vol. 8, article 900 (2017); Bianchini et al., Front. Microbiol., vol. 6, pp. 1433 (2015); Ravindran et al., J. Biotechnol. Biomaterial., S, 13 (2012)].

BRIEF SUMMARY OF THE INVENTION

In continuation of our fungal-mediated bio-transformational research on biologically active steroids [Siddiqui et al., J. Adv. Res., vol. 24, pp. 69-78 (2020); Ibrahim et al., Steroids, vol. 162, article 108694 (2020); Hussain et al., RSC Adv., vol. 10(1), pp. 451-460 (2020); Atia-tul-Wahab et al., Bioorg. Chem., vol. 77, pp. 152-158 (2018); Choudhary et al., Front. Pharmacol., vol. 8, article 900 (2017); Bano et al., PLOS One, vol. 11(4), article e0153951 (2016)], and on the basis of reported biological importance of testolactone (1), we focused on whole-cell biocatalysis of compound 1 by using fungi. In the present research work, biotransformation of testolactone (1) with Cunninghamella blakesleeana, and Macrophomina phaseolina was carried out at room temperature using aqueous media. This yielded five new metabolites, 7α-hydroxy-3-oxo-13,17-secoandrosta-1,4-dieno-17,13α-lactone (2), 7β-hydroxy-3-oxo-13,17-seco-5β-androsta-1-eno-17,13α-lactone (3), 3α,11β-dihydroxy-13,17-seco-5β-androsta-17,13α-lactone (4), 4β,5β-epoxy-3β-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (5), and 4β,5β-epoxy-3α-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (6). Their structures were determined by ¹H-, ¹³C-, and 2D-NMR, HREI-MS, HRFAB-MS, and IR spectral data.

In general, aromatase enzyme is present in high quantity in placenta, and in granulosa cells of ovarian follicles, depending on stimulation of cyclical gonadotropin. In the current study, the anti-aromatase activity of new structural analogues 2-6, of anti-cancer aromatase inhibitor testolactone (1) was determined in a pool of human fresh placental microsomes in vitro.

Based on reported anti-aromatase activity of drug 1, new transformed products 2-6 were evaluated against human placental microsomal aromatase to check their level of differential inhibition potential against the enzyme. Among them, metabolites 3 (IC₅₀=0.00863±0.0004 μM; 8.63±0.402 nM), and 4 (IC₅₀=0.00923±0.0013 μM; 9.23±1.310 nM) were identified as potent inhibitors against aromatase, in comparison to the substrate (anti-cancer aromatase inhibitor testolactone, 1) (IC₅₀=0.716±0.031 μM), and the standard aromatase inhibitor, exemestane (IC₅₀=0.232±0.031 μM). Derivatives 2 (IC₅₀=11.68±0.73 μM), 5 (IC₅₀=10.37±0.50 μM), and 6 (IC₅₀=0.82±0.059 μM) also showed a good inhibitory potential against aromatase enzyme.

New metabolites 2-6 were identified as non-cytotoxic against breast cancer cell lines, e.g., MCF-7, MDA-MB-231, and BT-474. New transformed products 2-6 were found to be inactive to normal cell lines, including BJ (human fibroblast), and 3T3 (mouse fibroblast).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the structures of testolactone (1), and its new metabolite, 7α-hydroxy-3-oxo-13,17-secoandrosta-1,4-dieno-17,13α-lactone (2) via C. blakesleeana-mediated transformation of drug 1, along with their aromatase inhibition and cytotoxic activities against human fibroblast (BJ), and mouse fibroblast (3T3) cell lines.

FIG. 2 depicts the structures of testolactone (1) and its new metabolites, 7β-hydroxy-3-oxo-13,17-seco-5β-androsta-1-eno-17,13α-lactone (3), 3α,11β-dihydroxy-13,17-seco-5β-androsta-17,13α-lactone (4), 4β,5β-epoxy-3β-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (5), and 4β,5β-epoxy-3α-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (6) via M. phaseolina-mediated transformation of drug 1, along with their aromatase inhibition and cytotoxic activities against human fibroblast (BJ), and mouse fibroblast (3T3) cell line.

FIG. 3 depicts the computer-generated ORTEP drawing of final X-ray models of new derivatives 4-6.

DETAILED DESCRIPTION OF THE INVENTION Experimental Media Preparation

One-liter media for each fungus was prepared by mixing 10 g glucose, 5 g NaCl, 5 g peptone, 5 g KH₂PO₄, and 10 mL glycerol in 1 L distilled water for their maximum, and mature growth.

Fermentation

On the basis of small-scale screening results, 4 L of media for each fungus was prepared by mixing aforementioned ingredients. Media (4 L) was distributed into 20 Erlenmeyer flasks of 500 mL (200 mL in each), cotton plugged, and autoclaved at 121° C. The sterilized media was then cooled at room temperature, and inoculated with seed flasks of each fungal cell cultures under sterilized conditions. Fungal cell cultures containing flasks were placed for 3-4 days on rotary shaker (121 rpm). After the mature growth of C. blakesleeana, and M. phaseolina in each flask, 1 g of testolactone (1) (C₁₉H₂₄O₃) was dissolved in 10 mL of DMSO and dispensed (2 mL) in each fungal culture containing flasks. The flasks were then again placed on rotary shaker (121 rpm) at 25° C. for twelve days.

Extraction

After incubation, the reaction was stopped by addition of DCM (dichloromethane) in each flask, and filtered to separate fungal masses. Each filtrate (aqueous and organic phases) was separated by extracting with 20 L of DCM. Anhydrous Na₂SO₄ (sodium sulfate) was added in each organic layer to make them moisture free, filtered, and concentrated under reduced pressure.

Isolation and Purification

Each resulting crude (2 g) was fractionated by column chromatography (CC) with a mobile phase of hexanes-acetone. The polarity of mobile phase was increased by increasing 5-100% gradients of acetone. As a result, five main fractions, i.e., 1-5 were obtained, which were analyzed by thin layer chromatography (TLCs). The fractions were further purified through recycling reverse phase HPLC (LC-908; equipped with YMC M-80; 20-250 mm i.d. 4-5 μm). Compounds 2 (methanol-water; 7/3, R_(T)=33 min, 8.8 mg), 3 (methanol-water; 7/3, R_(T)=32 min, 22.3 mg), 4 (methanol-water; 6/4, R_(T)=36 min, 24.2 mg), 5 (methanol-water; 7/3, R_(T)=36 min, 8.1 mg), and 6 (methanol-water; 7/3, R_(T)=31 min, 7.1 mg) were purified from fractions 1-5, respectively. Substrate 1 was also recovered.

7α-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dieno-17,13α-lactone (2)

White solid; m. p. 233-234° C.; [α]_(D) ²⁵=129.1 (c 0.001, MeOH); IR (CH₃Cl): υ_(max) (cm⁻¹) 3433 (OH), 2944 (CH), 1659, 1618 (α,β-unsaturated ketone), 1720 (6-membered lactone carbonyl); HREI-MS m/z 316.1657 [M⁺] (C₁₉H₂₄O₄) (calcd. 316.1675); EI-MS m/z: 316.2 [M⁺]; ¹H-NMR (δ) (CDCl₃), H-1 (7.04, d; J_(1,2)=10.0 Hz), H-2 (6.25, dd; J_(2,1)=10.5 Hz; J_(2,4)=2.0 Hz), H-4 (6.12, s), H₂-6 (2.69, overlap; 2.53, overlap), H-7 (4.18, d; J_(7e,8)=J_(7,6)=2.5 Hz), H-8 (1.45, m), H-9 (1.72, m), H₂-11 (1.97, overlap; 1.51, overlap), H₂-12 (1.98, overlap; 1.64, m), H-14 (1.87, m), H₂-15 (2.11, m; 1.53, overlap), H₂-16 (2.66, overlap; 2.52, overlap), H₃-18 (1.35, s), H₃-19 (1.18, s); ¹³C-NMR (6) (CDCl₃), C-1 (154.5), C-2 (128.0), C-3 (185.4), C-4 (127.2), C-5 (163.4), C-6 (40.6), C-7 (67.1), C-8 (42.2), C-9 (43.5), C-10 (42.9), C-11 (23.0), C-12 (38.4), C-13 (82.7), C-14 (40.8), C-15 (19.4), C-16 (28.4), C-17 (171.1), C-18 (20.0), C-19 (18.3).

7β-Hydroxy-3-oxo-13,17-seco-5β-androsta-1-eno-17,13α-lactone (3)

White solid; m. p. 197-199° C.; [α]_(D) ²⁵=+231.3 (c 0.001, MeOH); IR (CH₃Cl): υ_(max) (cm⁻¹) 3455 (OH), 2942 (CH), 1675 (α,β-unsaturated ketone), 1714 (6-membered lactone carbonyl); HREI-MS m/z 318.1844 [M⁺] (C₁₉H₂₆O₄) (calcd. 318.1831); ELMS m/z: 318.3 [M⁺]; ¹H-NMR (δ) (CDCl₃), H-1 (6.81, d, J_(1,2)=10.2 Hz), H-2 (5.96, d, J_(2,1)=10.2 Hz), H₂-4 (2.60, overlap; 2.35, dd, J_(4a,4b)=17.2 Hz; J_(4,5)=4.4 Hz), H-5 (2.20, m), H₂-6 (1.86, overlap; 1.76, overlap), H-7 (3.79, m), H-8 (δ 1.35, overlap), H-9 (1.62, m), H₂-11 (1.74, overlap; 1.51, m), H₂-12 (2.08, dt, J_(12,12)=12.6 Hz; J_(12,11)=3.1 Hz), H-14 (δ 1.69, overlap), H₂-15 (δ 2.61, overlap; 1.85, overlap), H₂-16 (δ 2.68, overlap; 2.52, overlap), H₃-18 (1.36, s), H₃-19 (1.21, s); ¹³C-NMR (δ) (CDCl₃), C-1 (159.2), C-2 (127.9), C-3 (198.6), C-4 (39.4), C-5 (40.7), C-6 (37.4), C-7 (70.1), C-8 (44.6), C-9 (46.8), C-10 (37.9), C-11 (23.5), C-12 (39.4), C-13 (83.2), C-14 (44.0), C-15 (21.9), C-16 (29.0), C-17 (171.2), C-18 (20.4), C-19 (20.7).

3α,11β-Dihydroxy-13,17-seco-5β-androstano-17,13α-lactone (4)

White solid; m. p. 188-191° C.; [α]_(D) ²⁵=+11.6 (c 0.001, MeOH); IR (CH₃Cl): υ_(max) (cm⁻¹) 3431 (OH), 2931 (CH), 1702 (6-membered lactone carbonyl); HRFAB-MS (+ve) m/z 323.2233 [M+H]⁺ (C₁₉H₃₁O₄) (calcd. 323.2222); FAB-MS (+ve) m/z 323.1 [M+H]⁺; FAB-MS (−ve) m/z 321.2 [M−H]⁺; ¹H-NMR (δ) (CDCl₃), H₂−1 (1.89, overlap; 1.22, overlap), H₂−2 (1.71, overlap; 1.29, overlap), H-3 (3.64, m), H₂-4 (1.68, overlap; 1.53, overlap), H-5 (1.66, overlap), H₂-6 (1.73, overlap; 1.28, overlap), H₂-7 (1.83, overlap; 1.12, overlap), H-8 (1.69, overlap), H-9 (1.51, overlap), H-11 (4.32, br. d, 1.7 Hz), H₂-12 (2.08, dd, J_(12,12)=13.8 Hz; J_(12.11e)=3.1 Hz; 1.81, overlap), H-14 (1.30, overlap), H₂-15 (1.99, overlap; 1.50, overlap), H₂-16 (2.66, ddd, J_(16,16)=19.1 Hz; J_(16a,15a)=8.9; J_(16a,15b)=2.1 Hz; 2.53, m), H₃-18 (1.46, s), H₃-19 (1.09, s); ¹³C-NMR (6) (CDCl₃), C-1 (35.0), C-2 (30.7), C-3 (71.4), C-4 (36.0), C-5 (42.4), C-6 (25.8), C-7 (26.0), C-8 (33.1), C-9 (48.0), C-10 (34.8), C-11 (66.6), C-12 (47.4), C-13 (82.6), C-14 (43.7), C-15 (19.6), C-16 (28.7), C-17 (171.5), C-18 (23.2), C-19 (26.4); Single-crystal X-ray Data: crystal system, orthorhombic; space group, P2₁2₁2₁; unit cell dimensions, a=6.4517 (2) Å, α=90, b=12.2365 (3) Å, β=90, c=21.1261 (5) Å, γ=90; volume, 1667.83 (8) Å³; crystal size, 0.11×0.10×0.05 mm; density, 1.284 mg/m³; θ range, 4.18 to 68.22.

4β,5β-Epoxy-3β-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (5)

White solid; m. p. 192-193° C.; [α]_(D) ²⁵=+302.0 (c 0.001, MeOH); IR (CH₃Cl): υ_(max) (cm⁻¹) 3434 (OH), 2944 (CH), 1720 (6-membered lactone carbonyl); HR-EIMS m/z 318.1832 [M⁺] (C₁₉H₂₆O₄) (calcd. 318.1831); EI-MS m/z: 318.1 [M⁺]; ¹H-NMR (δ)(CDCl₃), H-1 (5.43, overlap), H-2 (5.41, overlap), H-3 (4.44, br. d, J_(3,2)=J_(3,4)=2.5 Hz), H-4 (13.29, br. d, J_(4,3)=1.5 Hz), H₂-6 (2.12, td, J_(6a,6b)=13.7; J_(6,7)=4.4 Hz; 1.21, m), H₂-7 (1.99, overlap; 1.08, overlap), H-8 (1.26, m), H-9 (1.04, m), H₂-11 (1.73, m; 1.37, overlap), H₂-12 (1.92, m; 1.59, m), H-14 (1.38, m), H₂-15 (1.99, m; 1.51, m), H₂-16 (2.67, m; 2.57, m), H₃-18 (1.31, s), H₃-19 (1.09, s); ¹³C-NMR (6) (CDCl₃), C-1 (134.9), C-2 (124.2), C-3 (65.5), C-4 (63.5), C-5 (65.2), C-6 (30.4), C-7 (28.9), C-8 (37.5), C-9 (51.7), C-10 (39.2), C-11 (23.0), C-12 (39.0), C-13 (82.8), C-14 (45.6), C-15 (19.9), C-16 (28.5), C-17 (171.1); C-18 (20.0); C-19 (16.3); Single-crystal X-ray Data: crystal system, orthorhombic; space group, P2₁2₁2₁; unit cell dimensions, a=7.0877 (2) Å, α=90, b=11.0304 (3) Å, β=90, c=20.3492 (5) Å, γ=90; volume, 1590.90 (7) Å³; crystal size, 0.24×0.15×0.11 mm; density, 1.329 mg/m³; θ range, 4.35 to 68.15.

4β,5β-Epoxy-3α-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (6)

White solid; m. p. 194-196° C.; [α]_(D) ²⁵=+28.6 (c 0.001, MeOH); IR (CH₃Cl): υ_(max) (cm⁻¹) 3437 (OH), 2944 (CH), 1720 (6-membered lactone carbonyl); HREI-MS m/z 318.1838 [M⁺] (C₁₉H₂₆O₄) (calcd. 318.1831); EI-MS m/z (%): 318.1 [M⁺] (54), 300.2 (49), 227.1 (23), 199.1 (21), 147.1 (37), 121.1 (100); ¹H-NMR (6) (CDCl₃), H-1 (5.59, overlap), H-2 (5.57, overlap), H-3 (4.50, br. t, J_(3,2)=J_(3,4)=1.4 Hz), H-4 (3.08, br. d, J_(4,3)=1.6 Hz), H₂-6 (2.15, overlap; 1.29, overlap), H₂-7 (2.01, overlap; 1.18, overlap), H-8 (1.31, overlap), H-9 (1.33, overlap), H₂-11 (1.71, overlap; 1.37, overlap), H₂-12 (1.98, overlap; 1.65, overlap), H-14 (1.46, m), H₂-15 (2.02, overlap; 1.55, overlap), H₂-16 (2.72, ddd, J_(16,16)=18.8 Hz; J_(16a,15a)=8.1 Hz; J_(16a,15b)=2.0 Hz; 2.65, m), H₃-18 (1.33, s), H₃-19 (1.11, s); ¹³C-NMR (δ) (CDCl₃), C-1 (137.2), C-2 (122.5), C-3 (64.2), C-4 (62.0), C-5 (63.7), C-6 (30.2), C-7 (28.7), C-8 (38.0), C-9 (52.9), C-10 (39.4), C-11 (22.7), C-12 (38.9), C-13 (82.9), C-14 (45.5), C-15 (19.9), C-16 (28.6), C-17 (171.1), C-18 (20.0), C-19 (16.9). Single-crystal X-ray Data: crystal system, monoclinic; space group, P2₁; unit cell dimensions, a=5.9716 (15) Å, α=90, b=14.040 (4) Å, β=100.909 (17), c=10.445 (2) Å, γ=90; volume, 860.0 (4) Å³; crystal size, 0.180×0.170×0.080 mm; density, 1.299 mg/m³; θ range, 4.310 to 68.221.

Human Placental Aromatase Inhibition Assay Protocol

The aromatase enzyme activity can be determined by measuring conversion of testosterone to 17β-estradiol, shown as follows:

The activity is determined in a 1 mL reaction mixture, containing protein (mainly aromatase enzyme) (2 mg/mL), testosterone (10 μM), potassium phosphate buffer (0.1 M) at pH 7.4, and 10 μL of test compound (0.1 mM). The reaction mixture was pre-incubated at 37° C. for 10 min. NADPH (1 mM) was then added, and incubated for 20 min. The reaction was terminated by adding 100 μL of trichloroacetic acid (10%, w/v). The reaction mixture was centrifuged for 10 min at 12,000 g, pellet was discarded, and the supernatant containing 17β-estradiol was extracted with 1 mL N-butylchloride. The extracted 17β-estradiol was then dried and the quantity of the product was determined by UPLC (column ACE Generix 5 μm C₁₈ 150×4.6 mm) using isocratic elution of the mobile phase containing triethylamine (0.1%) in ACN/H₂O (45:55, v/v), and pH 3.0 (adjusted by orthophosphoric acid) with a flow rate of 1.2 mL/min at 200 nm. Calculations were performed by following formula:

${\%\mspace{11mu}{Inhibition}} = {100 - {\frac{\left( {{Peak}\mspace{11mu}{area}\mspace{11mu}{of}\mspace{11mu}{test}\mspace{11mu}{sample}} \right)}{\left( {{Peak}\mspace{11mu}{area}\mspace{11mu}{of}\mspace{11mu}{control}} \right)} \times 100}}$

Results and Discussion

The HREI-MS (high resolution electron ionization mass spectrometry) of metabolite 2 showed the [M⁺] at m/z 316.1657 (C₁₉H₂₄O₄), indicating addition of an oxygen atom as a hydroxyl group in substrate 1 (m/z 300). Presence of hydroxyl group in compound 1 at C-7 was assigned on the basis of HMBC (heteronuclear multiple bond correlation spectroscopy) correlations of H-7 with C-5, C-8, and C-9, and H₂-6 with C-7 (δ 67.1). The structure was identified as 7α-hydroxy-3-oxo-13,17-secoandrosta-1,4-dieno-17,13α-lactone (2).

The HREI-MS of metabolite 3 displayed the [M⁺] at m/z 318.1844 (C₁₉H₂₆O₄), indicating addition of an oxygen atom, along with two hydrogen atoms in substrate 1 (m/z 300). Reduction between C-4/C-5 was inferred via ³J correlation of H₂-6 and H-1 with C-4. Hydroxyl group at C-7 was supported by HMBC correlations of H-7 with C-5, C-8 and C-9, and H₂-6 with C-7. The structure of compound 3 was identified as 7β-hydroxy-3-oxo-13,17-seco-5β-androsta-1-eno-17,13α-lactone.

The [M+H]⁺ of metabolite 4 was observed at m/z 323.2233 in the HRFAB-MS (high resolution fast atom bombardment spectrometry), 22 amu greater than the substrate 1 (m/z 300). Reduction in the ring A of derivative 4 was inferred through the HMBC correlations of H₂-1 and H₂-4 with C-2, C-3 and C-10. An OH group was placed at C-11, based on HMBC correlations of H-11 with C-9, C-10, and C-12. The structure of derivative 4 was determined as 3α,11β-dihydroxy-13,17-seco-5β-androstano-17,13α-lactone.

The HREI-MS of metabolite 5 presented its [M⁺] at m/z 318.1832, indicating addition of oxygen, and two hydrogen atoms in substrate 1 (m/z 300). Epoxidation between C-4/C-5, along with reduction at C-3 was inferred though the ²J and ³J correlations of H-2 with C-3 and C-4. The structure was deduced as 4β,5β-epoxy-3β-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone (5).

The [M⁺] of metabolite 6 in the HREI-MS was observed at m/z 318.1838, indicating the addition of an oxygen atom, along with two hydrogen atoms in substrate 1 (m/z 300). Reduction at C-3, along with epoxidation between C-4/C-5 was determined via the HMBC correlations of H-1 with C-5, and H-2 with C-3 and C-4. The structure of derivative 6 was identified as 4β,5β-epoxy-3α-hydroxy-13,17-secoandrosta-1-eno-17,13α-lactone.

Placement of β-OH at C-7, along with reduction between C-4/C-5 in compound 3 (IC₅₀=0.00863±0.0004 μM) has increased its anti-aromatase activity than substrate 1 (IC₅₀=0.716±0.031 μM). Similarly, β-OH at C-11, and reduction of olefinic groups at C-1, C-2, C-4, and C-5, and ketonic carbonyl C-3 into secondary alcohol (α-OH) in compound 4 (IC₅₀=0.00923±0.0013 μM) also increased its ant-aromatase activity. While epoxidation between C-4/C-5, along with reduction of ketone into alcohol (α-OH) in compound 6 (IC₅₀=0.82±0.059 μM) has not much affected its inhibition potential against placental microsomal aromatase. Likewise, epoxidation between C-4/C-5, along with reduction of ketone into alcohol (β-OH) in derivative 5 (IC₅₀=10.37±0.50 μM) has decreased its anti-aromatase activity, as compared to parent molecule, testolactone (1), and derivatives 2-4, and 6.

Presence of hormone receptors, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) in breast cancer cell lines make them responsive towards hormonal therapies. While the breast cancer negative for these hormone receptors are more difficult to treat, as they do not respond to hormonal therapies. High amount of estrogens in the body due to overexpression of aromatase enzyme, enhances the breast tumors growth. In general, breast cancer tissues have been reported to express more aromatase enzyme than the normal tissues of breast. Estrogens and androgens stimulate the growth of MCF-7 breast cancer cells. New derivatives 2-6 were found to be inactive to breast cancer cell lines, e.g., MCF-7 (ER+, PR+, and HER₂+), MDA-MB-231 (ER, PR, and HER₂−), and BT-474 (ER+, and HER₂+) in vitro. This showed structural alteration, in anti-cancer drug, testolactone (1) did not affect their cytotoxicity potential. 

What is claimed is:
 1. A method of treatment of diseases associated with the over-expression of aromatase enzyme, including breast cancer, and male infertility, comprising on administration of effective amount of newly developed aromatase inhibitors having formulae 2-6 or their isomers, salts or solvates, or co-crystals in suitable pharmaceutical excipients, adjuvant, carrier, or diluent to humans, and animals in need thereof.


2. Formulae 2-6 as in claim 1 are new steroidal-based potent aromatase inhibitors that reduces, inhibits, or abrogates activity of aromatase enzyme (IC₅₀=11.68±0.73 μM), and thereby can treat estrogen-responsive (ER+) breast cancer, and improving testosterone/estradiol (T/E) ratio levels in infertile male.
 3. Formulae 2-6 as in claim 1 can be synthesized by biotransformation of anti-cancer drug testolactone (1) or through the chemical synthesis.
 4. Formulae 2-6 as in claim 1 can also be used for the prevention of other diseases resulted from the over-expression of aromatase enzyme. 